CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 520 enrolled
Drug / intervention
Cisplatin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02784171
NCT02784171Phase 3Completed
CompareCT.gov

A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group·interventional·Posted May 26, 2016·Updated Dec 10, 2024

In Brief

A Phase 3 clinical trial evaluating Cisplatin, Pemetrexed, and 1 other intervention for Mesothelioma. Completed, enrolled 520 participants across 57 sites in 3 countries.

Detailed Summary

Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma
CountriesCanada, France, Italy
CollaboratorsNational Cancer Institute, Naples, Merck Sharp & Dohme LLC, Intergroupe Francophone de Cancerologie Thoracique

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 26, 2016
Enrollment StartNov 11, 2016
Primary CompletionOct 11, 2024
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 10.1 years ago

Interventions

Cisplatindrug

Pemetrexeddrug

Pembrolizumabdrug